Immunofoco develops CAR-T cell therapies that treat solid tumors as hematologic malignancies, utilizing platforms like Peri Cruiser® and SNR to enhance tumor infiltration and reduce toxicity. Their approach addresses the challenge of tumor metastasis and recurrence by effectively targeting circulating tumor cells and microlesions, aiming to improve long-term survival rates for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors present significant challenges due to metastasis, recurrence from circulating tumor cells (CTCs) and microlesions, and difficulties in CAR-T cell infiltration, leading to limited long-term survival for patients. Current CAR-T therapies often struggle with toxicity and the ability to overcome tumor heterogeneity.
Solution
Immunofoco is developing CAR-T cell therapies designed to treat solid tumors by targeting circulating tumor cells and microlesions, similar to how hematologic malignancies are treated. The company utilizes innovative platforms such as Peri Cruiser®, SNR, and T-Booster to enhance tumor infiltration, reduce toxicity, and improve the curative effect. This approach aims to address tumor heterogeneity and improve long-term survival rates for patients with solid tumors. Immunofoco's pipeline includes IMC001 (EpCAM CAR-T), IMC002 (CLDN18.2 CAR-T), and IMC008 (SNR CAR-T), all of which have received Orphan Drug Designations from the FDA for various solid tumor indications.
Target Audience
The primary target audience includes patients with solid tumors, as well as oncologists and medical professionals seeking advanced CAR-T cell therapies to improve treatment outcomes.
Features
- Peri Cruiser® platform to enhance CAR-T cell infiltration into solid tumors.
- SNR platform designed to reduce toxicity associated with CAR-T cell therapies.
- T-Booster platform to promote expansion of CAR-T cells within the tumor microenvironment.
- CTC Testing Platform for monitoring circulating tumor cells.
- IMC001 (EpCAM CAR-T) targeting EpCAM-positive epithelial advanced solid tumors.
- IMC002 (CLDN18.2 CAR-T) targeting gastric and pancreatic cancers.
- IMC008 (SNR CAR-T) for the treatment of gastric and pancreatic cancers.
- CMC platform with product design and POC laboratory, process development, GMP manufacturing, and QC facility.